SEC Tracker
Get the app

Neurocrine Biosciences NBIX

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Takes on a new financial obligation (2.03)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Neurocrine Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Exelixis EXEL public float $9.4B, Jul 4, 2025
  2. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
  3. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.